PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: marketing

A Phase II, Randomized, Double -blind, Placebo -controlled ...

Date: 16 May 2017 Supersedes: Page 1 of 97 TJ301 Protocol No.: CTJ301UC201 Solution for Injection Clinical Trial Protocol Leading Biopharm Limited CONFIDENTIAL CLINICAL TRIAL PROTOCOL A Phase II, Randomized, Double -blind, Placebo -controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients with Active Ulcerative Colitis Protocol Number: CTJ301UC201 Investigational Medicinal Product: TJ301 (solution for injection), also referred to as FE 999301 and Olamkicept Indication: Active Ulcerative Colitis Phase : 2 Investigators: Multicenter, international, across Mainland China, Taiwan, Republic of Korea and Australia Coordinating Investigator Prof.

• Change from Baseline to Weeks 4, 8, and 12 in exploratory biomarkers (erythrocyte sedimentation rate [ESR], C-reactive protein (CRP), IL-6, IL-6/sIL-6R complex, neutrophil and platelet count, faecal calprotectin). Study Design

Loading..

Tags:

  Rates, Sedimentation, Erythrocyte sedimentation rate, Erythrocyte

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of A Phase II, Randomized, Double -blind, Placebo -controlled ...

Related search queries